Advertisement
Singapore markets closed

  • Straits Times Index

    3,306.02
    +6.02 (+0.18%)
     

  • Nikkei

    38,596.47
    -36.55 (-0.09%)
     

  • Hang Seng

    18,028.52
    -306.80 (-1.67%)
     

  • FTSE 100

    8,237.72
    -34.74 (-0.42%)
     

  • Bitcoin USD

    64,378.54
    +152.07 (+0.24%)
     

  • CMC Crypto 200

    1,351.36
    -8.96 (-0.66%)
     

  • S&P 500

    5,464.62
    -8.55 (-0.16%)
     

  • Dow

    39,150.33
    +15.57 (+0.04%)
     

  • Nasdaq

    17,689.36
    -32.23 (-0.18%)
     

  • Gold

    2,334.70
    -34.30 (-1.45%)
     

  • Crude Oil

    82.34
    +0.17 (+0.21%)
     

  • 10-Yr Bond

    4.2570
    +0.0030 (+0.07%)
     

  • FTSE Bursa Malaysia

    1,590.37
    -2.32 (-0.15%)
     

  • Jakarta Composite Index

    6,879.98
    +60.66 (+0.89%)
     

  • PSE Index

    6,158.48
    -186.08 (-2.93%)
     

Adicet Bio Announces Poster Presentation of ADI-270 Preclinical Data at the 2024 European Hematology Association (EHA) Hybrid Congress

Business Wire
·1-min read

REDWOOD CITY, Calif. & BOSTON, May 14, 2024--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the acceptance of a poster presentation at the upcoming European Hematology Association (EHA) Hybrid Congress being held in Madrid, Spain from June 13-16, 2024.

Details of the poster presentation are as follows:

Title: ADI-270: An Armored Allogeneic Anti-CD70 CAR γδ T Cell Therapy Designed for Multiple Solid and Hematological Cancer Indications
Presenting Author: Yvan Chanthery, Ph.D.
Date & Time: June 14, 2024 at 18:00 CEST

ADVERTISEMENT

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of "off-the-shelf" gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240514346504/en/

Contacts

Adicet Bio., Inc.
Investor and Media Contacts

Anne Bowdidge
abowdidge@adicetbio.com

Janhavi Mohite
Stern Investor Relations, Inc.
212-362-1200
janhavi.mohite@sternir.com